Golimumab is a human IgG monoclonal antibody specific for human tumor necrosis factor alpha. Golimumab has been approved for use in rheumatological conditions; however, its use in inflammatory bowel disease is still being evaluated in clinical trials. We report a case of an exacerbation of ulcerative proctitis after starting on golimumab for ankylosing spondylitis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/MJT.0b013e31825e6089 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!